by Katelyn Jetelina in Your Local Epidemiologist
Ed note: Sir William Osler (1849–1919), a foundational figure in modern medicine, once stated: “The desire to take medicine is perhaps the greatest feature which distinguishes man from animals”.
“Peptides” is a very broad category, so each one lies on a spectrum ranging from “decades of human research” to “never been tested in humans.”
Evidence table for some peptides. Table by Your Local Epidemiologist
BPC-157 and TB-500, the two peptides generating a lot of attention right now, sit firmly in the “potentially promising animal studies” category. Rat studies show interesting effects: accelerated tendon and ligament healing, gut lining repair, reduced inflammation across multiple tissue types, and improved muscle recovery. TB-500 has even been studied and subsequently banned for use in racehorses, which tells you something about how seriously the performance world takes it, even without human data.
But animals aren’t humans. Rats heal differently, metabolize compounds differently, and are studied under controlled conditions that don’t reflect the complexity of human biology, health history, or dosing. There are many medicines that look remarkable in animals and fail, sometimes dangerously, in human trials.
For BPC-157, there are a few, very small human pilots, but no randomized controlled trials. TB-500 itself has not been studied in human trials, though its parent molecule (which isn’t identical), thymosin beta-4, has progressed to Phase I trials for specific conditions in China.
Other peptides that you see on social media may not even have evidence from animal studies.
In conclusion, the people currently using these compounds are, in effect, running an uncontrolled experiment on themselves. (continued on Page 2 or here)